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Abstract
Ornithine transcarbamylase (OTC) deficiency is the most common urea cycle defect. The clinical presentation in
female manifesting carriers varies both in onset and severity. We report on a female with insulin dependent
diabetes mellitus and recurrent episodes of hyperammonemia. Since OTC activity measured in a liver biopsy sample
was within normal limits, OTC deficiency was initially excluded from the differential diagnoses of hyperammonemia.
Due to moderately elevated homocitrulline excretion, hyperornithinemia-hyperammonemia-homocitrullinuria-
syndrome was suggested, but further assays in fibroblasts showed normal ornithine utilization. Later, when
mutation analysis of the OTC gene became available, a known pathogenic missense mutation (c.533C>T) in exon 5
leading to an exchange of threonine-178 by methionine (p.Thr178Met) was detected. Skewed X-inactivation was
demonstrated in leukocyte DNA. In the further clinical course the girl developed marked obesity. By initiating
physical activities twice a week, therapeutic control of both diabetes and OTC deficiency improved, but obesity
persisted. In conclusion, our case confirms that normal hepatic OTC enzyme activity measured in a single liver
biopsy sample does not exclude a clinical relevant mosaic of OTC deficiency because of skewed X-inactivation.
Mutation analysis of the OTC gene in whole blood may be a simple way to establish the diagnosis of OTC
deficiency. The joint occurrence of OTC deficiency and diabetes in a patient has not been reported before.
Keywords: Ornithine transcarbamylase deficiency, Ornithine carbamoyltransferase deficiency, OTC deficiency,
Urea cycle disorder, Insulin-dependent diabetes mellitus, Hyperammonemia, Insulin
Background
Ammonia which is predominantly formed by degrad-
ation of amino acids is bound as urea by action of the
urea cycle. Urea cycle defects (UCDs) are a group of
inborn errors of metabolism comprising 6 enzymatic
defects (five core enzymes and one activating enzyme)
as well as a mitochondrial ornithine/citrulline antiporter
defect. Among UCDs, ornithine transcarbamylase (ornithin
carbamoyltransferase, OTC, E.C. 2.1.3.3) deficiency (OMIM
#311250) is the most prevalent with an incidence of
1:14.000 newborns [1-4]. OTC, a mitochondrial matrix
enzyme, catalyzes the biosynthesis of citrulline from
ornithine and carbamoyl phosphate. The corresponding
gene is located on Xp11.4. While hemizygote males usu-
ally present with severe neonatal hyperammonemic coma
which often proves to be fatal [2,5], the clinical picture
in female carriers of this X-linked disease is extremely
variable, depending on the degree of inactivation of the
mutated X chromosome.
Survival is better among those who have late onset of
symptoms like some female carriers or males with only
slightly reduced OTC activity [6-8]. While neonatal on-
set cases are usually diagnosed reliably using biochem-
ical parameters (like excretion of large amounts of orotic
acid and uracil and a typical amino acid pattern with ele-
vated glutamine and very low or not detectable citrulline
levels) diagnosis may be more complicated in late onset
cases [9]. The mainstay of dietary treatment is protein
restriction with supplementation of essential amino acids
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to minimize nitrogen load [9]. An adequate intake of cal-
ories is necessary to prevent protein catabolism [10]. In
order to deplete the hepatic nitrogen pool, oral sodium
benzoate and/or sodium phenylbutyrate can be applied
to eliminate ammonia without stressing the urea cycle.
The only curative treatment of OTC deficiency available
is liver transplantation [9,11-15]. In this article we report
the joint occurrence of OTC deficiency and type 1 dia-
betes and describe the diagnostic pitfalls and challenges
of dietary therapy.
Case presentations
We report a female, the first child of non-consanguineous
German parents, who was born without complications
following an uneventful pregnancy. At 7 weeks of
age she had an episode of vomiting when formula re-
placed breast feeding. She was further breastfed until
6 months. She then received an adapted cow’s milk
formula. At the age of 9 months loss of psychomotor
abilities was observed together with fatigue, repeated
vomiting and diarrhoea. At the age of 11 months the
child was hospitalized. Her height was 75 cm (50th
percentile) and her weight 8.5 kg (25th percentile).
Liver and spleen were slightly enlarged. Reduced spon-
taneous movements and truncal hypotonia were no-
ticed. The child could neither sit nor crawl nor pull
herself up to stand. CT of the brain showed moderate
cortical atrophy. Laboratory investigations revealed el-
evated transaminases and hyperammonemia (Table 1).
Additional diagnostic parameters including amino acid
concentrations measured in plasma and urine and
orotic acid excretion (Table 2) suggested OTC defi-
ciency. Protein restriction (0.93 g/kg/day of natural
protein plus 0.5 g/kg/day of synthetic protein/essential
amino acids) was instituted and transaminases nor-
malized progressively within 2 weeks and ammonia
after one month (Table 1). In order to verify OTC
deficiency a liver needle biopsy was performed. Liver
histology revealed pericentral fine-meshed fibrosis
with faint portal filament augmentation without signs
of inflammation. Low-grade intracellular accumulation
of fat droplets of variable sizes was noticed. Unexpectedly,
OTC activity in hepatic tissue was normal (261 nmol/
min/mg liver protein, normal values >160 nmol/min/mg
liver protein). Therefore, by exclusion, hyperornithinemia-
hyperammonemia-homocitrullinuria syndrome (HHH
syndrome, OMIM #238970) was considered, especially,
because homocitrulline was intermittently detectable
in urine. However, ornithine concentrations were al-
ways within the normal range, even during a 7-day trial
of ornithine supplementation for diagnostic purposes.
Substitution with citrulline (200–400 mg/kg/d according
to arginine level) was introduced. Waste nitrogen excre-
tion by alternate pathways was enhanced by sodium
benzoate and lactulose was given to limit reabsorption
of ammonia in the gut. Under this regimen, the girl
remained clinically stable during the following years ex-
cept for several metabolic decompensations with only
mild hyperammonemia. The physical and psychomotor
development was normal.
At the age of 4 years, the girl developed insulin-
dependent diabetes (islet-cell antibodies positive, but
insulin antibodies negative). The treatment had now to
include carbohydrate control and insulin injections fol-
lowing a 2 insulin injection regime. The further clinical
course was characterized by intermittent periods of
both hyperammonemia and ketoacidosis, which were
readily controlled by sodium benzoate (up to 350 mg/
kg/d), arginine-HCl (2 mmol/kg/d) and glucose-insulin
infusions as well as oral phenylbutyrate (100–300 mg/
kg/d) during several hospital stays. Later on, diabetes
management was switched to intensive insulin therapy
(4 insulin injection regime). Nevertheless, diabetes
treatment was suboptimal and HbA1c levels were inter-
mittently elevated up to 111 mmol/mol Hb (normal
20–42 mmol/mol Hb).
Table 1 Decline of ALAT, ASAT and ammonia after
starting of a protein-restricted diet at the age of
11 months
Day Ammonia (μmol/l) ALAT (U/l)* ASAT (U/l)*
normal range 15–
55 μmol/l
normal range <
22 U/l
normal range <
15 U/l
1 365 516 444
2 360 1215 1010
8 start of protein restriction (0.93 g/kg/d)
15 52 122 26
34 38 25 22
44 45 11 16
*measured at 25°C.
Table 2 Diagnostic parameters in plasma and urine
before treatment at the age of 11 months
Parameter Patient results Reference range
Ornithine in plasma 30 μmol/l 39-61 μmol/l
Glutamine in
plasma
2100 μmol/l 60-470 μmol/l
Arginine in plasma 70 μmol/l 53-71 μmol/l
Citrulline in plasma not detected no reference range
given
Lysine in plasma 500 μmol/l 107-163 μmol/l
Homocitrulline in
urine
17 mmol/mol creatinine not detectable
Orotic acid in urine > 8280 mmol/mol
creatinine
1.3-8.5 mmol/mol
creatinine
Grünert et al. Journal of Diabetes & Metabolic Disorders 2013, 12:37 Page 2 of 5
http://www.jdmdonline.com/content/12/1/37
Since homocitrullinuria was inconsistent and always
remained discrete, the suggested diagnosis was chal-
lenged. In order to prove or disprove the diagnosis of
HHH syndrome 14C-ornithine incorporation in fibro-
blasts was measured (14C-ornithine/3H-leucine ratio
0.368; controls 0.392; 0.401; known HHH syndrome:
14C-ornithine/3H-leucine ratio 0.033). The normal result
excluded a defect of the SLC25A15 ornithine transporter
and thereby HHH syndrome. Because of marked in-
creases of orotic acid excretion especially during meta-
bolic decompensations, OTC deficiency was again
suspected despite normal liver OTC activity. Mutation
analysis of the OTC gene, which had not yet been avail-
able at the time of OTC enzyme analysis, confirmed car-
rier status of OTC deficiency with a known pathogenic
heterozygous missense mutation in the OTC gene
(c.533C>T, p.Thr178Met). Furthermore, a skewed X-
inactivation with a ratio of (1:2.13) was noted in
leukocyte DNA (Figure 1). This finding supports the sus-
picion that a clinical relevant hepatic mosaic of OTC de-
ficiency might have been missed by a single liver biopsy.
The changed diagnosis did not alter the dietary therapy
and medication. The patient’s mother was also investi-
gated genetically, but no OTC mutation could be
detected.
As a complication of her diet, the girl developed pro-
gressive obesity. At the age of 15 years, she reached a
BMI of 32.3 kg/m2. At that time she started a sports
program with other diabetic adolescents and performed
physical activities twice a week. Subsequently, her dia-
betes control improved, HbA1c-levels decreased from
86 mmol/mol Hb to 60 mmol/mol Hb and serum
fructosamine levels from 497 to 290 μmol/l (normal
208–269 μmol/l). Moreover, during that time no hospi-
talizations because of hyperammonemia or ketoacidosis
were necessary. However, during the following years, her
compliance to therapy was not always satisfactory and
HbA1c values ranged from 62–89 mmol/mol.
The patient finished school and became a nurse. Her
psychomotor development is normal. IQ-testing at the age
of 26 years revealed an IQ of 94 (Wechsler Intelligenztest
für Erwachsene). Now, at the age of 27 years, she lives an
independent adult live and works as a nurse in an inten-
sive care unit.
Methods
The ornithine transporter assay was performed as de-
scribed before by Shih et al. [16]. Liver enzyme activity
of OTC was determined according to Raijman [8].
Genomic DNA was isolated from peripheral blood leu-
kocytes using proteinase K/sodium dodecyl sulfate treat-
ment and phenol/dichloromethane extraction [17].
Mutation analysis of the OTC gene was performed by
bidirectional sequencing of all 10 exons including adja-
cent intronic sequences. Exons 7 and 8 were amplified
as a single PCR product including intron 7 (80 bp).
X-inactivation analysis was performed by a PCR methy-
lation assay for the human androgen receptor (HUMARA)
Figure 1 X-inactivation analysis demonstrating skewed inactivation in the female patient, assessed from leukocyte DNA using the
HUMARA method. X-chromosomal alleles from an undigested control sample are shown in the upper panel. By HpaII digestion of a second
sample, which leads to restriction of unmethylated DNA, an unequal methylation status and thereby skewed X-inactivation of the X-chromosomal
alleles can be identified, as shown in the lower panel.
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gene locus comparing HpaII digested versus undigested
samples, as described previously [18]. PCR products of
X-chromosomal alleles were analyzed on a ABI3130xl
capillary sequencer (Applied Biosystems) and visualized by
Peak Scanner Software v1.0 (Applied Biosystems). For
each sample, absolute values for the major peak heights of
the two alleles were determined (ignoring any stutter
peaks) and converted into relative peak heights, based on
the sum of both allele peaks as 100%. Peak ratios were
calculated by dividing the signal of the allele with the lon-
ger fragment size by the signal of the allele with the
shorter fragment size.
Discussion
OTC deficient males are often severely affected [5]
whereas female carriers present with a wide phenotypic
variability [19,20]. Some may be entirely asymptomatic,
while others have severe hyperammonemia leading to
brain damage or death [9,21]. This clinical variability is
explained by X-inactivation in the liver. In females,
X-inactivation is a random process inactivating either
the maternal or the paternal allele. If X-inactivation
results in predominant expression of the mutated allele,
female carriers may be affected due to decreased OTC
enzyme activity. In our patient a skewed X-inactivation
pattern was found in leukocytes (see Figure 1). It has
been shown by Yorifuji et al. that the X-inactivation pat-
tern may differ significantly even within the same hep-
atic tissue but correlates well with the OTC activity in
all liver samples [21]. Thus, it was concluded that a sin-
gle liver biopsy is not adequate for the assessment of re-
sidual enzyme activity in females. This is underlined by
our case where normal OTC activity was detected in a
single liver biopsy despite symptomatic OTC deficiency.
Therefore, according to the recently published guidelines
for the diagnosis of urea cycle disorders [9] mutation
analysis of the OTC gene is the diagnostic gold standard
and permits to identify carrier females. However, in
about 20% of patients the mutation is not identified with
standard techniques [22]. The c.533C>T mutation found
in our patient was first described in a male suffering
from severe neonatal onset OTC deficiency [23]. In the
majority of female patients and in some male patients
the mutation appears de novo and the mother is not a
disease carrier [9], as was the case in our patient.
To our knowledge, this is the first report on a symp-
tomatic female with OTC deficiency with additional
insulin-dependent diabetes.
In view of the two underlying diseases, a vicious cycle
aggravating metabolic decompensations in our patient can
be hypothesized: In case of insulin deficiency, glucose
cannot enter the cells properly, thus leading to energy
deficiency and catabolism. Apart from endogeneous pro-
tein catabolism resulting in hyperammonemia, increased
hepatic glucose production and decreased peripheral glu-
cose utilization may lead to hyperglycemia. The increased
blood glucose levels, in turn, might result in glucosuria
and loss of calories further enhancing catabolism and
thereby aggravating hyperammonemia. Several hospital
admissions were necessary for induction of anabolism by
intravenous glucose-insulin and fat infusions, but also for
intensified detoxification of ammonia by sodium benzoate
and phenylbutyrate supplementation.
There is a large body of evidence that, on average, dia-
betic patients have a higher body weight and body mass
index compared to healthy controls [24] and therefore
should control their calorie intake. On the other hand,
for patients with urea cycle disorders a sufficient calorie
intake is required to prevent catabolism. The diet of our
patient was complicated by the restriction of both carbo-
hydrates and protein due to her diabetes and OTC
deficiency, respectively. Subsequently, the resulting in-
creased fat intake may have contributed to obesity.
Regular physical activity did not only improve the
patient’s diabetes control, reflected by a marked decrease
in HbA1c levels and stabilization of blood glucose levels,
but also her metabolic control. Moderate physical exer-
cise may induce protein anabolism and simultaneously
lower glucose levels.
Conclusion
In conclusion, our case report illustrates that liver OTC
activity assays are not reliable in the diagnosis of OTC
deficiency in females due to the mosaicism caused by
X-inactivation. Mutation analysis of the OTC gene is a
safer and less invasive approach to confirm the diag-
nosis. Since OTC deficiency and diabetes have different
dietary implications the treatment is challenging.
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